Anticoagulant therapy

Findings from a real-world data analysis of the U.S. Medicare database comparing the risk of stroke or systemic embolism and...


A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found that atrial fibrillation...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa...


The European Society of Cardiology ( ESC ) has recommended uninterrupted anticoagulation with vitamin K antagonists during ablation and device...


Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Clot prevention with anticoagulants might...


The important factor for efficacy and safety for patients with atrial fibrillation undergoing electrical cardioversion ( ECV ) is appropriate...


The FDA approved Pradaxa in 2010 to prevent stroke and systemic blood clots in patients with atrial fibrillation, as well...


The recent availability of Dabigatran ( Pradaxa ), a novel oral anticoagulant, provided a new treatment option for stroke prevention...


The results from two analyses of the GLORIA-AF Registry Program examining the use of antithrombotic treatment to reduce the risk...



The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulants ( OACs ) is currently debated. Search for...


The first non-vitamin K antagonist oral anticoagulant ( NOAC ) introduced to the market in Japan was Dabigatran ( Pradaxa...


The 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension are published in the European Heart Journal and...


European Xarelto ( Rivaroxaban ) product information has now included guidance for use in patients with atrial fibrillation undergoing cardioversion. The...


A FDA ( Food and Drug Administration ) study of more than 134,000 Medicare patients found that Pradaxa ( Dabigatran...


The coagulation system contributes greatly to the evolution of myocardial infarction ( MI ). Anticoagulation may reduce the occurrence of...


A study has assessed the safety and efficacy of less aggressive anticoagulation with an international normalized ratio ( INR )...


Venous and arterial thromboses have been regarded for many years as two different diseases requiring anticoagulant or antiplatelet treatment, respectively....


Antiarrhythmic drugs ( AADs ) and anticoagulation are mainstays of atrial fibrillation ( AF ) treatment. A study has assessed...


Final data from a phase 2 comparator-controlled study evaluating the incidence of venous thromboembolic events ( VTE ) in patients...